a Semmelweis Egyetem
15 nap
-1 óra
9 perc
39 mp

Az előadások bárminemű felhasználása a szerzők engedélye nélkül szigorúan tilos!

Nagy P. 1st Institute of Pathology and Experimental Cancer Research, SU:
Imatinib preserves the functional organization and amends regeneration of liver in CDE fed mice

Döme B. Department of Thoracic Surgery, SU:
Tumor vascularization

Tímár J, Rásó E.. 2nd Department of Pathology, SU:
IFN resistance of melanoma

Kéri Gy. HAS-SU Pathobiochemistry Research Unit:
In vitro combination therapy based on driver genes

Enyedi A. HAS-SU Molecular Oncology Research Unit:
Ca++ signaling in BRAF mutant melanoma

Dietel M. Charité, Berlin:
Molecular pathology in XXIst century

Győrffy B, HAS-SU Lendület program:
Computing offtarget-effect by cross-analysis of transcriptome-level data from 1,118 studies

Jalkanen M, Pharon Pharmeceuticals:
SME as a central link between the bench and the bedside

Matolcsy A. 1st Institute of Pathology and Experimental Cancer Research, SU:
Molecular diagnostics of lymphomas

Kiss A. 2nd Department of Pathology, SU:
Predictive markers of Sorafenib sensitivity of HCC

Lakatos P. 1st Department of Ínternal Medicine, SU:
Molecular pathology of thyroid cancers

Szász AM, 2nd Department of Pathology:
Gene expression based novel prognostic factors in breast cancer

Hegedűs B. Department of Thoracic Surgery, Medical University of Vienna:
Oncogenic mutations of the EGFR pathway in lung adenocarcinoma

Igaz P. 2nd Department of Internal Medicine, SU:
MicroRNAs and genomics in adrenal tumors

Schmoll HJ, Martin-Luther University Halle-Wittenberg:
Current standards and new targets in colorectal cancer